CURRENT DERMATOLOGY CLINICAL TRIALS​​

​

Castle Biosciences - Malignant Melanoma

Outcomes of Cutaneous Melanoma Patients Clinically Tested with DecisionDx®-Melanoma: A Prospective Registry (CONNECTION PRO)

While previous studies have demonstrated a significant difference in metastatic risk for patients with Class 1 and Class 2 tumor biology, evaluation of DecisionDx®-Melanoma in a large prospective cohort of clinically tested patients would allow for a broad analysis of the test performance, prognostic accuracy in AJCC substages, and clinical, pathological, and molecular integration.

​

Therefore, the goal of this study is to determine outcomes for patients who are clinically evaluated with DecisionDx®-Melanoma. This expanded data set will allow for an extensive analysis of the prognostic value of DecisionDx®-Melanoma in all patients. Further, creation of a biobank for residual sample storage for patients clinically tested with DecisionDx®-Melanoma will expedite multiple avenues of melanoma research both at Castle Biosciences, Inc (CBI) and at other centers through future collaborations.

​

Castle Biosciences - Squamous Cell Carcinoma (SCC)

Clinical Utility and Health Outcomes Study of the DecisionDx®-SCC Prognostic Gene Expression Profile Test (UTILISE)

This is a multicenter, prospective study to evaluate the utility of DecisionDx®-SCC results on physician recommendations regarding follow-up, surveillance, and therapeutic management, as well as healthcare outcomes for cSCC patients. Data will be collected via review of medical records and investigator-completed management assessment tools.

​

This study will establish a clinical registry to address important scientific and medical questions concerning the clinical application of the DecisionDx®-SCC test by gathering data on patterns of test utilization, the distribution of results across clinicopathologic variables, and the impact on physician recommendations for clinical management of cSCC patients.